Menu Search
Equities

Prothena Corporation PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0PT:DUS

Prothena Corporation PLC

Actions
  • Price (EUR)7.30
  • Today's Change-0.05 / -0.68%
  • Shares traded200.00
  • 1 Year change-42.52%
  • Beta--
Data delayed at least 15 minutes, as of Feb 11 2026 11:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

  • Revenue in USD (TTM)11.79m
  • Net income in USD-280.46m
  • Incorporated2012
  • Employees163.00
  • Location
    Prothena Corporation PLC77 Sir John Rogerson's QuayBlock C, Grand Canal DocklandsDUBLIN D02 VK60IrelandIRL
  • Phone+353 12362500
  • Fax+353 19023510
  • Websitehttps://www.prothena.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.